SAB Biotherapeutics Statistics
Total Valuation
SABS has a market cap or net worth of $179.95 million. The enterprise value is $75.26 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SABS has 47.61 million shares outstanding. The number of shares has increased by 11.66% in one year.
| Current Share Class | 47.61M |
| Shares Outstanding | 47.61M |
| Shares Change (YoY) | +11.66% |
| Shares Change (QoQ) | +737.29% |
| Owned by Insiders (%) | 3.97% |
| Owned by Institutions (%) | 10.84% |
| Float | 22.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,568.94 |
| Forward PS | n/a |
| PB Ratio | 1.09 |
| P/TBV Ratio | 1.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 656.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.50, with a Debt / Equity ratio of 0.04.
| Current Ratio | 10.50 |
| Quick Ratio | 10.32 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -174.11 |
Financial Efficiency
Return on equity (ROE) is 18.56% and return on invested capital (ROIC) is -25.38%.
| Return on Equity (ROE) | 18.56% |
| Return on Assets (ROA) | -22.76% |
| Return on Invested Capital (ROIC) | -25.38% |
| Return on Capital Employed (ROCE) | -25.02% |
| Revenue Per Employee | $1,821 |
| Profits Per Employee | -$68,064 |
| Employee Count | 63 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.80% in the last 52 weeks. The beta is 0.59, so SABS's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -7.80% |
| 50-Day Moving Average | 3.49 |
| 200-Day Moving Average | 2.34 |
| Relative Strength Index (RSI) | 51.77 |
| Average Volume (20 Days) | 317,215 |
Short Selling Information
The latest short interest is 901,471, so 1.89% of the outstanding shares have been sold short.
| Short Interest | 901,471 |
| Short Previous Month | 702,326 |
| Short % of Shares Out | 1.89% |
| Short % of Float | 3.99% |
| Short Ratio (days to cover) | 3.34 |
Income Statement
In the last 12 months, SABS had revenue of $114,698 and -$4.29 million in losses. Loss per share was -$2.23.
| Revenue | 114,698 |
| Gross Profit | -30.33M |
| Operating Income | -43.19M |
| Pretax Income | 18.74M |
| Net Income | -4.29M |
| EBITDA | -40.09M |
| EBIT | -43.19M |
| Loss Per Share | -$2.23 |
Full Income StatementBalance Sheet
The company has $110.88 million in cash and $6.19 million in debt, giving a net cash position of $104.69 million or $2.20 per share.
| Cash & Cash Equivalents | 110.88M |
| Total Debt | 6.19M |
| Net Cash | 104.69M |
| Net Cash Per Share | $2.20 |
| Equity (Book Value) | 165.07M |
| Book Value Per Share | 3.48 |
| Working Capital | 102.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$37.53 million and capital expenditures -$55,377, giving a free cash flow of -$37.59 million.
| Operating Cash Flow | -37.53M |
| Capital Expenditures | -55,377 |
| Free Cash Flow | -37.59M |
| FCF Per Share | -$0.79 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -37,657.13% |
| Pretax Margin | 16,338.32% |
| Profit Margin | 16,338.32% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.66% |
| Shareholder Yield | -11.66% |
| Earnings Yield | -2.38% |
| FCF Yield | -20.89% |
Analyst Forecast
The average price target for SABS is $10.50, which is 177.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.50 |
| Price Target Difference | 177.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 142.28% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 5, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jan 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
SABS has an Altman Z-Score of -0.07 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.07 |
| Piotroski F-Score | 1 |
